SCHEMBL3717293

SCHEMBL3717293

Clc1ccc2c(c1Cl)NCCC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 5/20 0.53
NOTUM Q6P988 1/20 0.46
HTR2A P28223 5/20 0.44
HTR2C P28335 5/20 0.44
HTR2B P41595 4/20 0.44
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
MPI P34949 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8529317 0.88 NOTUM (0.53) PNMTNOTUMHTR2AHTR2CHTR2B
SCHEMBL9510659 0.81 PNMT (0.42) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL22389359 0.81 PNMT (0.39) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL10911499 0.81 KDM4E (0.39) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL10913735 0.81 HTR2C (0.47) PNMTHTR2AHTR2CHTR2BMAPT
SCHEMBL19511770 0.80 SRC (0.46) PNMTMAPTKDM4EMEN1ALDH1A1
SCHEMBL10911889 0.77 AR (0.37) PNMTHTR2AHTR2CHTR2BMAPT
SCHEMBL10911422 0.77 PNMT (0.39) PNMTNOTUMHTR2AHTR2CHTR2B
SCHEMBL12604283 0.77 PNMT (0.36) PNMTMAPTKDM4EMEN1ALDH1A1
SCHEMBL5759503 0.76 SRC (0.49) PNMTHTR2CHTR2BADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280024-A1 RENIN INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2010-11-04 US disclosed
EP-2205559-A1 RENIN INHIBITORS Cadila Healthcare Limited (IN) 2010-07-14 EP disclosed
WO-2009087649-A1 RENIN INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2009-07-16 WO disclosed
US-4623377-A PREEMERGENCE NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-11-18 US disclosed
EP-0158954-A2 Tetrahydroquinolin-1-yl carbonyl imidazole derivatives, their intermediates; process for their preparation and herbicides or fungicides for agriculture or horticulture NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1985-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280024-A1 RENIN INHIBITORS REN, ACE, AGTR1 PNMT 1409/4885NOTUM 1050/4885HTR2A 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.